Todays Report: Today, The Zacks Investment Research Downgrade Karyopharm Therapeutics Inc. (KPTI) to Hold

Today, The Zacks Investment Research Downgrade Karyopharm Therapeutics Inc. (KPTI) to Hold

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.

According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

Other equities analysts have also recently issued reports about the stock. S&P Equity Research reduced their price target on shares of Karyopharm Therapeutics from $9.06 to $7.55 in a research report on Tuesday, August 30th. Jefferies Group reissued a “buy” rating and set a $12.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday, September 8th. HC Wainwright lifted their price target on shares of Karyopharm Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, September 8th. Vetr cut shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating and set a $11.00 price target on the stock. in a research report on Wednesday, August 31st. Finally, Canaccord Genuity set a $20.00 price target on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Saturday, August 6th. One analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $15.47.

Karyopharm Therapeutics (NASDAQ:KPTI) opened at 9.29 on Friday. Karyopharm Therapeutics has a 52-week low of $4.83 and a 52-week high of $18.84. The firm’s 50-day moving average is $8.72 and its 200 day moving average is $8.35. The firm’s market capitalization is $383.15 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Monday, November 7th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.12. Equities analysts anticipate that Karyopharm Therapeutics will post ($3.00) EPS for the current year.

In other Karyopharm Therapeutics news, insider Ran Frenkel sold 3,309 shares of the business’s stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $10.06, for a total transaction of $33,288.54. Following the sale, the insider now directly owns 14,691 shares of the company’s stock, valued at approximately $147,791.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 14.79% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System raised its position in Karyopharm Therapeutics by 0.6% in the third quarter. California State Teachers Retirement System now owns 49,844 shares of the company’s stock valued at $485,000 after buying an additional 300 shares in the last quarter. ProShare Advisors LLC raised its position in Karyopharm Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 29,655 shares of the company’s stock valued at $199,000 after buying an additional 376 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Karyopharm Therapeutics by 1.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 60,498 shares of the company’s stock valued at $406,000 after buying an additional 882 shares in the last quarter. BlackRock Advisors LLC raised its position in Karyopharm Therapeutics by 15.1% in the third quarter. BlackRock Advisors LLC now owns 11,410 shares of the company’s stock valued at $111,000 after buying an additional 1,498 shares in the last quarter. Finally, Swiss National Bank raised its position in Karyopharm Therapeutics by 7.3% in the second quarter. Swiss National Bank now owns 36,850 shares of the company’s stock valued at $247,000 after buying an additional 2,500 shares in the last quarter. Institutional investors own 56.26% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Related posts

Leave a Comment